Cell Therapy Starting Material: How to Source for RUO, Process Development, and GMP Manufacturing
Lab Director · OrganaBio · June 2026
Starting material is where CGT programs win or lose consistency
Cell and gene therapy manufacturing begins with a biological input — primary human cells — that behaves differently from donor to donor, lot to lot, and format to format. Unlike small molecule synthesis where you start with a defined chemical compound, CGT manufacturing starts with a living organism’s cells, and those cells carry the variability of the person they came from.
Managing that variability starts with sourcing strategy. The decisions made about starting material — which cell type, which donor population, which grade, which supplier — shape every downstream process step. This guide covers what to source at each development stage and how to avoid the transition issues that create delays when programs advance.
Starting material by therapy type
| Therapy Type | Primary Starting Material | Key Sourcing Considerations |
|---|---|---|
| Autologous CAR-T | Patient apheresis (T cells) | Patient health status, collection timing relative to treatment history, processing turnaround |
| Allogeneic CAR-T | Healthy donor leukopak / T cells | HLA type, T cell subset composition, donor recallability, GMP path |
| CAR-NK therapy | Healthy donor NK cells (CD56+CD3-) | NK cell frequency, activation status, donor recallability |
| TCR-T therapy | Healthy donor T cells | HLA restriction for TCR matching, T cell health markers |
| Gene therapy (ex vivo) | CD34+ HSCs (cord blood or mobilized) | CD34+ frequency, viability post-cryopreservation, processing time from collection |
| MSC therapy | Mesenchymal stromal cells (cord tissue, placenta) | Tri-lineage differentiation capacity, immunosuppressive function markers |
Research phase: what to optimize for
In early research — target identification, construct screening, initial process exploration — the primary concern is consistency within your experiments. You need enough cells from the same donor to run parallel conditions, and you need the cells to be healthy and well-characterized so you understand what you’re working with.
At this stage, RUO starting material is appropriate. What to look for in an RUO source:
- Immunophenotype data included with the order. You want to know the T/NK/B cell frequency in your PBMC or leukopak prep before you start — not infer it from your experimental results.
- Donor recallability. If an experiment works, you want to reorder from the same donor for the follow-up. Switching donors mid-study is a confound.
- Processing time transparency. Know how long from collection to your bench. Short processing times (under 30 minutes from receipt to first spin) preserve cell function better than extended hold times.
Process development phase: building the case for GMP transition
During process development, your starting material choices begin to define your manufacturing process. The cell isolation method you use, the activation protocol, the transduction or editing conditions — all are optimized against the specific type of starting material you’re running.
Two sourcing decisions at this stage have large downstream consequences:
Deciding whether to process leukopaks in-house or use pre-isolated cells. In-house isolation gives you control over the process and costs less per cell but requires equipment and trained personnel. Pre-isolated T or NK cells cost more per vial but simplify the process and reduce operator-to-operator variability. The right choice depends on your lab’s throughput and what your process will look like at manufacturing scale.
Choosing a supplier with a GMP path. If you begin process development with an RUO supplier that has no GMP-compliant collection program, you will face a supplier change — and associated process comparability work — when you advance to IND-enabling studies. Qualifying a GMP supplier during process development, before you need them, eliminates this bottleneck.
IND-enabling and Phase I manufacturing: the documentation standard
At the IND stage, starting material is no longer just a lab reagent — it is a defined component of a clinical manufacturing process with regulatory expectations. Key requirements that become relevant:
- Donor eligibility determination per 21 CFR Part 1271 or equivalent international regulation
- Infectious disease testing using FDA-cleared or approved test methods
- Documented processing SOPs referenced in the batch record
- Certificate of Analysis with release criteria that you or your CDMO can review and accept
- Chain of custody documentation from donor apheresis to final product release
- Supplier qualification — audit rights, quality agreement, SOP review
These are not requirements that appear at Phase I and disappear. They set the documentation standard that will be expected for the entire clinical program. The more completely a supplier can support these requirements, the less build-out is needed on the sponsor’s side.
Cord blood CD34+ HSCs: different source, same logic
For gene therapy programs targeting hematopoietic stem cells, cord blood-derived CD34+ cells are a common starting material. The sourcing logic is similar to peripheral blood programs, with additional considerations:
- Processing time is more critical. CD34+ cells from cord blood begin to decline in colony-forming potential within hours of collection. OrganaBio’s cord blood processing protocol runs under 24 hours from collection to cryopreservation, preserving CD34+ viability and function.
- CD34+ frequency per unit varies. Cord blood CD34+ frequency is lower than mobilized peripheral blood — typically 0.5–2% of nucleated cells vs. 0.5–5% in mobilized collections. Unit selection and pooling strategy matter.
- Birth tissue network access. Cord blood availability is constrained by birth tissue collection infrastructure. Suppliers with owned birth tissue networks — rather than purchased units — have more reliable supply and chain-of-custody transparency.
MSC starting material: the birth tissue advantage
Mesenchymal stromal cells (MSCs) used in regenerative medicine and immunomodulation research are most commonly derived from cord tissue or placenta — both components of the birth tissue collected at delivery. This is a structural advantage for suppliers with owned birth tissue programs: they control the entire chain from donation consent through processing, without purchasing from a secondary biobank.
OrganaBio’s MesenPAC product line is derived from our owned birth tissue network. MSC characterization includes the standard tri-lineage differentiation panel (adipogenic, osteogenic, chondrogenic) and surface marker profile (CD73+/CD90+/CD105+ positive; CD14-/CD34-/CD45-/HLA-DR- negative).
Sourcing checklist for CGT starting material
Before committing to a starting material supplier for a CGT program, confirm:
- Does the supplier offer the cell type and format your process requires?
- Is donor recallability available — can you re-collect the same donor for subsequent runs?
- What immunophenotype and donor characterization data is included in the standard order?
- What is the supplier’s processing time from collection to release — and how is it documented?
- Does the supplier have a GMP-compliant collection program, or only RUO?
- What does the GMP documentation package include — CoA, donor eligibility records, batch records?
- Has the supplier been qualified by a sponsor or CDMO, and can they provide audit-ready documentation?
- What is the supplier’s donor pool size and recallability rate?
